Abstract
After chemotherapy, tumor cells tend to become more aggressive, making it challenging for natural and adaptive immune responses to fight them. This often results in recurrence and metastasis, leading to higher mortality rates. The purpose of this study is to discover the mechanisms that cause chemotherapy resistance, including altered expression of immune checkpoints, in a colorectal cancer cell line. We used conventional methods to culture the SW-1116 colorectal cancer cell line in this study. The MTT assay was used to determine the IC50 and efficacy of Docetaxel and Doxorubicin. After treatment, quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to analyze PD-L1, CTLA-4, and VISTA gene expression in the SW-1116 cell line. The upregulation of VISTA expression showed a significant increase (p < 0.0001) in response to both chemotherapy agents. Moreover, the expression of CTLA-4 exhibited a remarkable level of significance (p < 0.0001), and PD-L1 expression also displayed notable significance (p < 0.0001). Chemotherapeutic agents heighten immune checkpoint gene expression, highlighting potential immune response pathway modulation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
This article presents a comprehensive compilation of all relevant material. For more clarification or elaboration, please reach out to the corresponding author.
References
Alipour S et al (2024) Glyburide-treated human monocyte-derived dendritic cells loaded with insulin represent tolerogenic features with anti-inflammatory responses and modulate autologous T cell responses in vitro. Int Immunopharmacol 126:111230
Black M et al (2016) Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. Oncotarget 7(9):10557–10567
Blank C, Mackensen A (2007) Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 56:739–745
Chen L et al (2014) Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 5(1):5241
Concha-Benavente F et al (2016) Identification of the cell-intrinsic and-extrinsic pathways downstream of EGFR and IFNγ that induce PD-L1 expression in head and neck cancer. Can Res 76(5):1031–1043
Cunningham D et al (2010) Colorectal cancer. Lancet 375(9719):1030–1047
Deng L et al (2014) Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Investig 124(2):687–695
Derakhshani A et al (2021) Cytotoxic T-lymphocyte antigen-4 in colorectal cancer: another therapeutic side of capecitabine. Cancers (Basel) 13(10):2414
Edwardson DW, Parissenti AM, Kovala AT (2019) Chemotherapy and inflammatory cytokine signalling in cancer cells and the tumour microenvironment. Advances in Experimental Medicine and Biology 1152:173–215. In book: Breast Cancer Metastasis and Drug Resistance (pp.173–215)
Flavell RA et al (2010) The polarization of immune cells in the tumour environment by TGFβ. Nat Rev Immunol 10(8):554–567
Ghavami S et al (2009) Apoptosis and cancer: mutations within caspase genes. J Med Genet 46(8):497–510
Greenwald RJ, Freeman GJ, Sharpe AH (2005) The B7 family revisited. Annu Rev Immunol 23:515–548
Huang KC-Y et al (2020) Decitabine augments chemotherapy-induced PD-L1 upregulation for PD-L1 blockade in colorectal cancer. Cancers 12(2):462
Jabbari N et al (2020) Modulation of immune checkpoints by chemotherapy in human colorectal liver metastases. Cell Rep Med 1(9):100160
Kondo Y et al (2016) Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma. Oral Oncol 57:54–60
Kurtova AV et al (2015) Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature 517(7533):209–213
Li TT et al (2021) Identification of active small-molecule modulators targeting the novel immune checkpoint VISTA. BMC Immunol 22(1):55
Li N et al (2023) Chemotherapy induces immune checkpoint VISTA expression in tumor cells via HIF-2alpha. Biochem Pharmacol 210:115492
Majidi M et al (2021a) The effects of chemotherapeutic drugs on PD-L1 gene expression in breast cancer cell lines. Med Oncol 38(12):147
Majidi M et al (2021b) The effects of chemotherapeutic drugs on PD-L1 gene expression in breast cancer cell lines. Med Oncol 38:1–8
Mittal D et al (2014) New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape. Curr Opin Immunol 27:16–25
Modest DP, Pant S, Sartore-Bianchi A (2019) Treatment sequencing in metastatic colorectal cancer. Eur J Cancer 109:70–83
Morgan E et al (2023) Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut 72(2):338–344
Naba NM et al (2020) Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells. Turk J Biol 44(1):15–23
Salonga D et al (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6(4):1322–1327
Shan J et al (2022) Mechanism and strategies of immunotherapy resistance in colorectal cancer. Front Immunol 13:1016646
Shi SJ et al (2013) B7–H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PLoS ONE 8(10):e76012
Sung H et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249
Van Der Kraak L et al (2016) 5-Fluorouracil upregulates cell surface B7–H1 (PD-L1) expression in gastrointestinal cancers. J Immunother Cancer 4:1–8
Vermeulen L et al (2010) Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12(5):468–476
Vincent J et al (2010) 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell–dependent antitumor immunity. Can Res 70(8):3052–3061
Wu CW, Lui RN (2022) Early-onset colorectal cancer: current insights and future directions. World J Gastrointest Oncol 14(1):230–241
Yang S et al (2021) Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity. Biomaterials 272:120791
Yu M et al (2017) Tim-3 is upregulated in human colorectal carcinoma and associated with tumor progression. Mol Med Rep 15(2):689–695
Zhong G et al (2018) Expression of STING and PD-L1 in colorectal cancer and their correlation with clinical prognosis. Int J Clin Exp Pathol 11(3):1256–1264
Zou W, Chen L (2008) Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8(6):467–477
Acknowledgements
We express our gratitude to the research personnel affiliated with the Immunology Research Center, Tabriz University of Medical Sciences, for their valuable support in conducting the experimental procedures.
Funding
The authors have not disclosed any funding.
Author information
Authors and Affiliations
Contributions
HN and MAY developed the study design collaboratively and created the foundational conceptual framework, while BB and BM provided essential biological materials and reagents. During the experimentation phase, HN, ZV, and DA made contributions. The analysis of the collected data was carried out by MAY, ensuring statistical accuracy and alignment with research inquiries. The manuscript was initially drafted by KMA, FJ, and FRB. Subsequent revisions were made by MS and MA to enhance the content and coherence. The entire study was overseen and supervised by BB, who ensured comprehensive oversight.
Corresponding author
Ethics declarations
Competing Interests
The authors have not disclosed any competing interests.
Ethical Approval
The investigation was approved by Tabriz University of Medical Science’s medical ethics committee, and the ethics Identification Number is IR.TBZMED.VCR.REC.1402.077. This research was carried out by the principles of the Helsinki Declaration.
Consent for Publication
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Ahmadpour Youshanlui, M., Nasiri, H., Valedkarimi, Z. et al. Impact of Doxorubicin and Docetaxel on Immune Checkpoint Expression in Colorectal Cancer: Insights into Chemotherapy Resistance Mechanisms. Biochem Genet (2024). https://doi.org/10.1007/s10528-024-10796-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s10528-024-10796-4